Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0016719 (
Friedreich's ataxia
)
2,098
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Detailed in vivo and in vitro studies of glucose and insulin metabolism in
Friedreich's ataxia
patients and unaffected family members have further defined the extent of the abnormalities in carbohydrate metabolism. The high incidence of glucose intolerance and a hyperinsulinemic response to a glucose challenge in a high percentage of
Friedreich's ataxia
patients has been confirmed. An increased incidence of glucose intolerance among heterozygotes is suggested, while the siblings show a more normal distribution of diabetes and a nearly normal insulin response to the glucose tolerance test. Human
growth hormone
patterns are normal for all groups. Preliminary studies of insulin binding to erythrocytes suggest a difference in the binding characteristics among diabetic
Friedreich's ataxia
patients, while the binding in the non-diabetic
Friedreich's ataxia
group is similar to that of non-diabetic controls. Results from a small group of non-diabetic siblings suggest a normal insulin binding, while a tendency toward increased binding at low insulin concentrations among diabetic family members is noted.
...
PMID:Glucose tolerance and erythrocyte insulin receptors in Friedreich's ataxia. 48 16
We have characterized the abnormalities of glucose metabolism associated with
Friedreich's ataxia
(FA) by studying plasma glucose, insulin,
growth hormone
(GH), and glucagon before and after an oral glucose tolerance test (OGTT), an IV glucose load, and an IV arginine load, in 21 patients and in controls. Twelve patients were normotolerant (NT) to glucose, five glucose-intolerant (IT), and four diabetic (DM). Insulin secretion of IT patients was increased and delayed during OGTT. Interestingly, the insulin release during arginine load was significantly decreased in NT and IT as well as in DM patients. The GH response to OGTT was altered in IT patients. Plasma glucagon after an arginine load was significantly higher in patients than in controls. The results indicate that FA is associated with insulin resistance, beta-cell deficiency, and type I diabetes. These alterations might be genetically linked or metabolically related to the primary defect in FA. Their interplay or independent effects are responsible for abnormalities of glucose metabolism in FA.
...
PMID:Glucose metabolism alterations in Friedreich's ataxia. 304 13
Oral glucose tolerance, thyroid function tests, as well as thyrotropin, prolactin and
growth hormone
release after administration of thyrotropin releasing hormone, were evaluated in patients with
Friedreich's ataxia
and unaffected family members. Impaired glucose tolerance was found in the majority of family members, affected or not. Thyroid hormone levels and PRL and TSH responses to TRH, were similar in all and normal. However, GH responses to TRH were abnormal in half of the patients, but in none of the unaffected family members. Paradoxical responses to neuropeptides may characterize some
Friedreich's ataxia
patients, and may predict the possibility of therapeutic maneuvers with such peptides in these patients.
...
PMID:Pituitary responses to a neuroactive tripeptide (TRH) in Friedreich's ataxia families. 680 4
As part of an ongoing search for diabetes susceptibility loci, we tested linkage with non-insulin-dependent diabetes mellitus (NIDDM) for 19 candidate loci or regions chosen for their potential to affect directly or indirectly the action of insulin. Loci were associated with insulin resistance, known effects on lipid metabolism, or effects on glucose metabolism or insulin action. Loci included the insulin-responsive (GLUT4) glucose transporter, hexokinase 2, glucagon,
growth hormone
, insulin receptor substrate 1 (IRS1), phosphoenolpyruvate carboxykinase, hepatic and muscle forms of pyruvate kinase, hepatic phosphofructokinase, the apolipoprotein B and the apolipoprotein A2 cluster, lipoprotein lipase, hepatic triglyceride lipase, the very-low-density-lipoprotein receptor, and the Pima insulin resistance locus on chromosome 4. For several candidates, no specific informative marker was available; consequently, we tested the surrounding region with highly informative markers. These regions included the diabetes-associated ras-like gene, rad, and the cholesterol ester-transfer gene, both mapped to chromosome 16. Additionally, we tested for linkage with markers at the tumor necrosis factor-alpha gene and the
Friedreich's ataxia
region. All regions were tested for linkage with microsatellite polymorphisms in > 450 individuals from a minimum of 16 Caucasian families under parametric (LINKAGE 5.1) and nonparametric (affected pedigree member) models.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Linkage analysis of 19 candidate regions for insulin resistance in familial NIDDM. 758 21
Friedreich ataxia
is a progressive degenerative disease with neurologic and cardiac involvement. This study characterizes comorbid medical conditions in a large cohort of patients with
Friedreich ataxia
. Patient diagnoses were collected in a large natural history study of 641 subjects. Prevalence of diagnoses in the cohort with
Friedreich ataxia
was compared with prevalence in the population without
Friedreich ataxia
. Ten patients (1.6%) had inflammatory bowel disease, 3.5 times more common in this cohort of individuals with
Friedreich ataxia
than in the general population. Four subjects were
growth hormone
deficient, reflecting a prevalence in
Friedreich ataxia
that is 28 times greater than the general population. The present study identifies specific diagnoses not traditionally associated with
Friedreich ataxia
that are found at higher frequency in this disease. These associations could represent coincidence, shared genetic background, or potentially interactive disease mechanisms with
Friedreich ataxia
.
...
PMID:Comorbid Medical Conditions in Friedreich Ataxia: Association With Inflammatory Bowel Disease and Growth Hormone Deficiency. 2707 70